Monitor upcoming AAN presentations in April 2026 for pivotal SPS and gMG data, which could serve as key catalysts. The extended cash runway into 2028 reduces near-term dilution risk, but continued losses suggest future financing may be needed post-launch.
Price Chart
Executive Summary
Kyverna Therapeutics reported financial results for Q4 and full year 2025, highlighted by strong clinical progress in its lead autoimmune CAR T candidate miv-cel, including pivotal data in stiff person syndrome (SPS) and advancement of its Phase 3 trial in generalized myasthenia gravis (gMG). The company has $279.3 million in cash, projecting runway into 2028, supporting an anticipated BLA submission for SPS in 1H 2026 and commercial launch preparation.
Key Financial Metrics
Key Facts
- Miv-cel achieved statistically significant results in the registrational KYSA-8 trial for stiff person syndrome (SPS), with no high-grade CRS or ICANS, supporting potential outpatient use.
- BLA submission for SPS anticipated in 1H 2026; primary data to be presented at AAN in April 2026.
- Phase 3 trial in generalized myasthenia gravis (gMG) is enrolling, with first patient dosed in December 2025.
- Cash and equivalents totaled $279.3 million as of December 31, 2025, providing expected runway into 2028.
- Net loss increased to $161.3 million in 2025 from $127.5 million in 2024, driven by higher R&D and G&A expenses.
Financial Impact
Increased operating expenses led to a 26.5% year-over-year increase in net loss, from $127.5M to $161.3M, despite stable cash position due to recent financings.
Risk Factors
- Clinical results from prior trials may not predict future outcomes; regulatory approval not guaranteed.
- Increased net loss reflects rising costs ahead of commercialization, increasing financial burn rate.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263388 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | $5.57 (−4.55%) |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | $5.57 (−20.39%) |
Aug 11, 2026 10w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.57 (−30.87%) |
Aug 11, 2026 10w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.57 (−30.87%) |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | $5.57 (−29.73%) |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | $5.57 (−43.27%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | $5.57 (+30.91%) |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | $5.57 (−38.17%) |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | $5.57 (−45.60%) |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | $5.57 (−50.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers